Patents Assigned to TMEM16A LIMITED
  • Compounds for treating respiratory disease
    Patent number: 12552770
    Abstract: Compounds of general formula (I) and their tautomeric forms all enantiomers and isotopic variants and salts and solvates thereof: wherein represents a single or a double bond and R1, R2, X1, X2, X3, X4, X5, Y and Z are as defined herein; are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: February 17, 2026
    Assignee: TMEM16A Limited
    Inventors: Stephen Collingwood, Clive Mccarthy, Duncan Alexander Hay, Jonathan David Hargrave, Albert Ma, Thomas Beauregard Schofield, Matthew Smith, Edward Walker, Naomi Went, Peter Ingram, Christopher Stimson, Someina Khor
  • Pyridine derivatives as calcium-activated chloride channel modulators
    Patent number: 12545658
    Abstract: Compounds of general formula (I), wherein R1, R2, R3, R4, R5, X1, X2 and X3 are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: February 10, 2026
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Craig Buxton, Matthew Habgood, Jonathan David Hargrave, Thomas Beauregard Schofield, Matthew Smith, Christopher Stimson
  • Modulators of TMEM16A for treating respiratory disease
    Patent number: 12415793
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, A, Z1, Z2 and Y are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: September 16, 2025
    Assignee: TMEM16A Limited
    Inventors: Stephen Collingwood, Jonathan David Hargrave, Duncan Alexander Hay, Edward Walker
  • Compounds
    Patent number: 12377105
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R5b X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: August 5, 2025
    Assignee: TMEM16A Limited
    Inventors: Stephen Collingwood, Clive McCarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker
  • Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide
    Patent number: 12281077
    Abstract: The invention relates to novel forms of N-tert-Butyl-4-[[2-(5-chloro-2-hydroxy-phenyl)acetyl]amino]pyridine-2-carboxamide (Compound 1). In particular, the invention relates to the Form A and Form B crystalline polymorphs and the amorphous form.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: April 22, 2025
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Robert Melling
  • BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE
    Publication number: 20240132467
    Abstract: Compounds of general formula (I): (I) wherein R1, R2, R3, R4, R5, Y and Z are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.
    Type: Application
    Filed: June 9, 2023
    Publication date: April 25, 2024
    Applicant: TMEM16A Limited
    Inventors: Stephen COLLINGWOOD, Jonathan David Hargrave, Duncan Alexander Hay, Clive McCarthy, Thomas Beauregard Schofield, Edward Walker, Naomi Went
  • Compounds
    Patent number: 11364246
    Abstract: Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: June 21, 2022
    Assignee: TMEM16A LIMITED
    Inventors: Stephen Collingwood, Clive Mccarthy, Jonathan David Hargrave, Duncan Alexander Hay, Thomas Beauregard Schofield, Sarah Ellam, Craig Stephen Buxton, Matthew Habgood, Peter Neville Ingram, Chun Yan Ma, Spencer Charles Robert Napier, Abdul Kadar Shaikh, Matthew Raymond Smith, Christopher Charles Stimson, Edward Richard Walker